Related Experiment Video
Updated: Apr 5, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Novel psoriasis therapies and patient outcomes, Part 3: Systemic medications
Meghan A Feely1, Barry L Smith, Jeffrey M Weinberg
1Department of Dermatology, Icahn School of Medicine at Mount Sinai, Mount Sinai St. Luke's-Roosevelt, 1090 Amsterdam Ave, Ste 11B, New York, NY 10025, USA. mfeely@chpnet.org.
Abstract:
The therapeutic armamentarium for patients with psoriasis and psoriatic arthritis (PsA) has been strengthened by research affording more individualized treatment regimens with new therapeutic targets. In this article, new systemic therapies for psoriasis are discussed, including a review of the relevant clinical trials for novel therapeutics and their respective mechanisms of action, patient outcomes, and safety profiles. This article is the final installment in a 3-part series on agents in the pipeline for the management of psoriasis and PsA including topical agents, biologic treatments, and systemic therapies in phase 2 through phase 4 clinical trials. These systemic agents offer patients more targeted treatment regimens with the prospect of enhanced therapeutic efficacy and more favorable side-effect profiles with better tolerability.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Acne Infection
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Psychosis: Goals of Pharmacotherapy
